GENFIT S A/ADR (NASDAQ:GNFT) Downgraded by Zacks Investment Research to “Sell”

Share on StockTwits

Zacks Investment Research cut shares of GENFIT S A/ADR (NASDAQ:GNFT) from a hold rating to a sell rating in a research note released on Tuesday morning, Zacks.com reports.

According to Zacks, “Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company’s lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France. “

A number of other equities research analysts also recently commented on GNFT. HC Wainwright lowered their price target on shares of GENFIT S A/ADR to $72.00 and set a buy rating for the company in a report on Monday, April 22nd. Svb Leerink assumed coverage on shares of GENFIT S A/ADR in a report on Wednesday, April 24th. They set an outperform rating and a $58.00 price target for the company. Barclays assumed coverage on shares of GENFIT S A/ADR in a report on Monday, April 22nd. They set an overweight rating and a $55.00 price target for the company. Roth Capital reiterated a buy rating on shares of GENFIT S A/ADR in a report on Tuesday, April 23rd. Finally, Leerink Swann assumed coverage on shares of GENFIT S A/ADR in a report on Wednesday, April 24th. They set an outperform rating and a $25.47 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $52.62.

Shares of NASDAQ GNFT opened at $18.78 on Tuesday. GENFIT S A/ADR has a 12 month low of $18.35 and a 12 month high of $26.25. The business’s 50-day moving average price is $21.52.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Victory Capital Management Inc. purchased a new stake in GENFIT S A/ADR in the first quarter valued at approximately $2,358,000. TT International purchased a new stake in GENFIT S A/ADR in the first quarter valued at approximately $1,200,000. One68 Global Capital LLC purchased a new stake in GENFIT S A/ADR in the first quarter valued at approximately $270,000. Finally, Dean Capital Investments Management LLC purchased a new stake in GENFIT S A/ADR in the first quarter valued at approximately $650,000. Institutional investors and hedge funds own 15.31% of the company’s stock.

GENFIT S A/ADR Company Profile

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Read More: How do CD ladders protect against rising interest rates?

Get a free copy of the Zacks research report on GENFIT S A/ADR (GNFT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GENFIT S A/ADR (NASDAQ:GNFT)

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Kin  Market Cap Reaches $16.51 Million
Kin Market Cap Reaches $16.51 Million
ARBITRAGE  Reaches Market Cap of $477,120.00
ARBITRAGE Reaches Market Cap of $477,120.00
DAV Coin  Achieves Market Cap of $522,367.00
DAV Coin Achieves Market Cap of $522,367.00
OST  Reaches Market Cap of $8.36 Million
OST Reaches Market Cap of $8.36 Million
VanEck Vectors Junior Gold Miners ETF  Trading 5.4% Higher
VanEck Vectors Junior Gold Miners ETF Trading 5.4% Higher
Halliburton  Trading Down 5.1%
Halliburton Trading Down 5.1%


 
© 2006-2019 Zolmax.